Cargando…
Spironolactone Improves the All-Cause Mortality and Re-Hospitalization Rates in Acute Myocardial Infarction with Chronic Kidney Disease Patients
Background: Mineralocorticoid receptor antagonists (MRA) improve outcomes in chronic kidney disease (CKD) and acute myocardial infarction (AMI) patients. However, the lack of evidence regarding long-term clinical outcomes in the use of MRA, including spironolactone, in patients with AMI combined wit...
Autores principales: | Qu, Xiang, Yao, Hui, Chen, Changxi, Kong, Shuting, Sun, Lingyue, Du, Leilei, Liang, Siqi, Gao, Zhan, Zheng, Gaoshu, Zheng, Minghua, Zhao, Chuhuan, Feng, Xiafei, Wu, Gaojun, Zhou, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201517/ https://www.ncbi.nlm.nih.gov/pubmed/34135751 http://dx.doi.org/10.3389/fphar.2021.632978 |
Ejemplares similares
-
(Re) Solving Repair After Myocardial Infarction
por: Leoni, Giovanna, et al.
Publicado: (2018) -
Effects of spironolactone and losartan on the early neovascularization of acute myocardial infarction
por: LIU, YAN, et al.
Publicado: (2014) -
Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction
por: Minicucci, Marcos F., et al.
Publicado: (2013) -
Efficacy of Spironolactone Treatment in Murine Models of Cutaneous and Visceral Leishmaniasis
por: Andrade-Neto, Valter Viana, et al.
Publicado: (2021) -
Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk
por: Li, Jun-Feng, et al.
Publicado: (2023)